Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!

Home
report store
large granular lymphocytic leukemia lgll epidemiology forecast

SALE

Large Granular Lymphocytic Leukemia (LGLL) - Epidemiology Forecast-2034

Published Date : 2025

Pages : 70

Region : United States, Japan, EU4 & UK

SALE

Summary
TOC Table of Content
LOT
- Sample Request

large granular lymphocytic leukemia lgll epidemiology forecast

DelveInsight's "Large Granular Lymphocytic Leukemia (LGLL) - Epidemiology Forecast-2034" report delivers an in-depth understanding of the LGLL, historical and forecasted epidemiology as well as the LGLL trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Geography Covered

The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2021-2034

LGLL Understanding

The DelveInsight’s LGLL epidemiology report gives a thorough understanding of LGLL by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. Large granular lymphocytic leukemia (LGLL), is a chronic blood disorder with an increased number of large granular lymphocytes (LGLs) in the peripheral blood that accumulate over time. LGLs are characterized by enlarged lymphocytes containing noticeable granules, which can be observed under microscopic examination. In normal conditions, LGLs comprise about 10 to 15 percent of peripheral blood mononuclear cells, but in LGLL, the cases are characterized by extremely high number of LGLs in blood; either by higher number of LGLs than normal, or by a higher percentage compared to other types of white blood cells. Although there are no well-established causes and risk factors of LGLL, it is often times associated with some mutations (like STAT3 and STAT5b), associated comorbidities, age and some common manifestations.

Symptoms of LGLL can range from fatigue and B symptoms (fever, night sweat, and weight loss), changes in blood cell counts like anemia, neutropenia and thrombocytopenia, which can also lead to recurrent infections in certain cases, to splenomegaly, hepatomegaly, and even lymphadenopathy. Although it should be noted that about 30% of the patients are asymptomatic at the time of diagnosis.

Diagnosis

Since the signs and symptoms of LGLL are not very distinctive, with them overlapping with many other diseases and the fact that almost a third of the diagnosed patients are observed to be asymptomatic at the time of diagnosis, making a definite diagnosis for LGLL quite a necessity.

A definite LGLL diagnosis requires evidence of a chronic expanded clonal T- or NK-cell LGL population associated with an appropriate clinical context. It is based on cytology, immunophenotype analysis, and evidence of monoclonality. LGLL can be diagnosed by conducting several tests, including a complete blood count (CBC), usually the first test to show the main sign of LGLL, high white blood cell count and low neutrophil count; flow cytometry with an LGL Panel, which can show the presence of LGLL type; T-cell receptor gene rearrangement (TCR) further tests for types of T-cell clones; bone marrow biopsy; splenectomy and spleen analysis

LGLL Epidemiology

The epidemiology section provides insights about the historical and current LGLL patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted LGLL epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2021 to 2034.

In the year 2021, the total diagnosed incidence cases of LGLL were about 3840 cases in the 7MM which are expected to grow during the study period, i.e., 2021-2034.

The disease epidemiology covered in the report provides historical as well as forecasted LGLL epidemiology [segmented as Total diagnosed incidence cases, Total type-specific cases of LGLL, Total mutation-specific cases of LGLL, Total age-specific cases of LGLL, Total clinical manifestations-specific cases of LGLL and Total treated cases of LGLL by line of therapies] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2021 to 2034.

Country Wise- LGLL Epidemiology

The epidemiology segment also provides the LGLL epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

KOL- Views

To keep up with the current LGLL patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the LGLL domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.

Scope of the Report

The report covers the descriptive overview of LGLL, explaining their causes, symptoms, pathophysiology, and genetic basis.
The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The report assesses the disease risk and burden and highlights the unmet needs of LGLL.
The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
The report provides the segmentation of the disease epidemiology for 7MM by total diagnosed incidence cases, total type-specific cases of LGLL, total mutation-specific cases of LGLL, total age-specific cases of LGLL, total clinical manifestations-specific cases of LGLL and total treated cases of LGLL by line of therapies.

Explore the key factors, trends, innovations, and developments driving the market growth, at: Large Granular Lymphocytic Leukemia (LGLL) Market

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence LGLL R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for LGLL
Our in-depth analysis of the pipeline assets across different stages of development, different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Leptomeningeal metastases Report Key Strengths

11 Years Forecast
7MM Coverage
LGLL Epidemiology Segmentation

Key Questions

Epidemiology Insights:

What are the disease risk, burden, and regional/ethnic differences of LGLL?
What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What is the historical Leptomeningeal metastases patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What would be the forecasted patient pool of LGLL in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
Where will be the growth opportunities in the 7MM concerning the patient population about LGLL?
Out of all 7MM countries, which country would have the highest prevalent population of LGLL during the forecast period (2025-2034)?
At what CAGR the patient population is expected to grow by 7MM during the forecast period (2025-2034)?

Reasons to buy

The report will help in developing business strategies by understanding trends shaping and driving the LGLL disease market
To understand the future market competition in the LGLL disease market and insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for LGLL disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
Identification of upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for the LGLL disease market
To understand the future market competition in the LGLL disease market

1. Key Insights

2. Report Introduction

3. LGLL Market Overview at a Glance

3.1. Market Share (%) Distribution of LGLL in 2021

3.2. Market Share (%) Distribution of LGLL in 2034

4. Executive Summary of LGLL

5. Epidemiology and Market Methodology

6. Disease overview and background

6.1. Introduction

6.2. Classification of LGLL

6.2.1. T-cell LGL leukemia (T-LGLL)

6.2.2. Chronic lymphoproliferative disorder of natural killer cells (CLPD-NK)

6.2.3. Aggressive natural killer cell leukemia (ANKL)

6.3. Etiology of LGLL

6.4. Clinical Presentation of LGLL

6.5. Manifestations Associated with LGLL

6.5.1. Autoimmune manifestations

6.5.2. Bone marrow failure and other hematologic neoplasms

6.6. Pathogenesis of LGLL

6.7. Genetic Mutations Involved in LGLL

6.7.1. Genetics of T-cell LGLL

6.7.2. Genetics of CLPD-NK

7. Diagnosis of LGL leukemia

7.1. Cytology

7.2. Immunophenotyping

7.3. Clonality

7.4. Molecular findings

7.5. Marrow features

7.6. Diagnostic algorithm

7.7. Differential diagnosis

8. Treatment

8.1. Treatment of Relapsed or Refractory Disease

8.1.1. Treating an aggressive NK-cell LGLL

8.1.2. Treatment algorithm

8.1.3. Treatment Guidelines of LGLL

9. Patient Journey

10. Epidemiology and Patient Population

10.1. Key Findings

10.2. Assumptions and Rationale 7MM

10.3. Epidemiology Scenario in the 7MM

10.3.1. Diagnosed Incidence Cases in the 7MM

10.3.2. Type-specific Cases of LGLL in the 7MM

10.3.3. Mutation-specific Cases of LGLL

10.3.4. Age-specific Cases of LGLL in the 7MM

10.3.5. Clinical manifestations-specific Cases of LGLL

10.3.6. Treated Cases of LGLL by line of therapies

10.4. Epidemiology Scenario in the United States

10.4.1. Diagnosed Incidence Cases in the United States

10.4.2. Type-specific Cases of LGLL in the United States

10.4.3. Mutation-specific Cases of LGLL in the United States

10.4.4. Age-specific Cases of LGLL in the United States

10.4.5. Clinical manifestations-specific cases of LGLL in the United States

10.4.6. Treated Cases of LGLL by line of therapies

10.5. Epidemiology Scenario in EU5

10.5.1. Diagnosed Incidence Cases in EU5

10.5.2. Type-specific Cases of LGLL in EU5

10.5.3. Age-specific Cases of LGLL in EU5

10.5.4. Clinical manifestations-specific cases of LGLL in EU5

10.5.5. Mutation-specific Cases of LGL in the EU5

10.5.6. Treated Cases LGLL by line of therapies

10.6. Epidemiology Scenario in Japan

10.6.1. Diagnosed Incidence Cases in Japan

10.6.2. Type-specific Cases of LGLL in the Japan

10.6.3. Mutation-specific Cases of LGLL

10.6.4. Age-specific Cases of LGLL in the Japan

10.6.5. Clinical manifestations-specific Cases of LGLL

10.6.6. Treated Cases of LGLL by line of therapies

11. Unmet Needs

12. Appendix

12.1. Acronyms and Abbreviations

12.2. Bibliography

12.3. Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

15. About DelveInsight

List of Tables:

List of Table

Table 1: Diagnosed Incident Cases of LGLL (2021-2034)

Table 2: Type-specific Cases of LGLL in the 7MM (2021-2034)

Table 3: Mutation-specific Cases of LGLL in the 7MM (2021-2034)

Table 4: Age-specific Cases of LGLL in the 7MM (2021-2034)

Table 5: Clinical manifestations-specific Cases of LGLL in the 7MM (2021-2034)

Table 6: Treated Cases of LGLL by line of therapies (2021-2034)

Table 7: Diagnosed Incidence Cases of LGLL in the United States (2021-2034)

Table 8: Type-specific Cases of LGLL in the United States (2021-2034)

Table 9: Mutation-specific Cases of LGLL in the United States (2021-2034)

Table 10: Age-specific Cases of LGLL in the United States (2021-2034)

Table 11: Clinical manifestations-specific Cases of LGLL in the United States (2021-2034)

Table 12: Treated Cases of LGLL by line of therapies in the United States (2021-2034)

Table 13: Diagnosed Incidence Cases of LGLL in EU5 (2021-2034)

Table 14: Type-specific Cases of LGLL in EU5 (2021-2034)

Table 15: Age-specific Cases of LGLL in EU5 (2021-2034)

Table 16: Stage-specific Cases of LGLL in EU5 (2021-2034)

Table 17: Mutation-specific Cases of LGLL in EU5 (2021-2034)

Table 18: Treated Cases of LGLL by line of therapies in EU5 (2021-2034)

Table 19: Diagnosed Incidence Cases of LGLL in Japan (2021-2034)

Table 20: Type-specific Cases of LGLL in the Japan (2021-2034)

Table 21: Mutation-specific Cases of LGLL in the Japan (2021-2034)

Table 22: Age-specific Cases of LGLL in the Japan (2021-2034)

Table 23: Clinical manifestations-specific Cases of LGLL in the Japan (2021-2034)

List of Figures:

List of Figures

Figure 1: Epidemiology and Market Methodology

Figure 2: Classification of LGLL

Figure 3: Common Etiopathogenesis for LGLL Associated With Autoimmune Disease

Figure 4: Signaling Pathways and Mutations Involved in the Pathogenesis of LGLs.

Figure 5: TAT3 and STAT5b Mutations are Preferentially Found in Phenotypically Distinct LGL Disorders

Figure 6: Diagnostic Algorithm of LGLL

Figure 7: Treatment Algorithm of LGLL

Figure 8: Treatment Algorithm of LGLL

Figure 9: Diagnosed Incidence Cases of LGLL in the 7MM (2021-2034)

Figure 10: Type-specific Cases of LGLL in the 7MM (2021-2034)

Figure 11: Mutation-specific Cases of LGLL in the 7MM (2021-2034)

Figure 12: Age-specific Cases of LGLL in the 7MM (2021-2034)

Figure 13: Clinical manifestations-specific Cases of LGLL in the 7MM (2021-2034)

Figure 14: Treated Cases of LGLL by line of therapies in the 7MM (2021-2034)

Figure 15: Diagnosed Incidence Cases of LGLL in the United States (2021-2034)

Figure 16: Type-specific Cases of LGLL in the United States (2021-2034)

Figure 17: Total Mutation-specific Cases of LGLL in the United States (2021-2034)

Figure 18: Age-specific Cases of LGLL in the United States (2021-2034)

Figure 19: Total clinical manifestations-specific Cases of LGLL in the United States (2021-2034)

Figure 20: Treated Cases of LGLL by line of therapies in the United States (2021-2034)

Figure 21: Diagnosed Incidence Cases of LGLL in the EU5 (2021-2034)

Figure 22: Type-specific Cases of LGLL in EU5 (2021-2034)

Figure 23: Age-specific Cases of LGLL in EU5 (2021-2034)

Figure 24: Clinical manifestations-specific Cases of LGLL in EU-5 (2021-2034)

Figure 25: Mutation-specific Cases of LGLL in EU5 (2021-2034)

Figure 26: Treated Cases of LGLL by line of therapies in EU5 (2021-2034)

Figure 27: Diagnosed Incidence Cases of LGLL in Japan (2021-2034)

Figure 28: Type-specific Cases of LGLL in the Japan (2021-2034)

Figure 29: Mutation-specific Cases of LGLL in the Japan (2021-2034)

Figure 30: Age-specific Cases of LGLL in the Japan (2021-2034)

Figure 31: Clinical manifestations-specific Cases of LGLL in the Japan (2021-2034)

Figure 32: Treated Cases of LGLL by line of therapies in the Japan (2021-2034)

Tags:

License Type

Offer